ID   COQ2_HUMAN              Reviewed;         371 AA.
AC   Q96H96; O95331; Q1JQ78; Q684R2;
DT   21-MAR-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   10-MAY-2017, entry version 128.
DE   RecName: Full=4-hydroxybenzoate polyprenyltransferase, mitochondrial {ECO:0000255|HAMAP-Rule:MF_03189};
DE            Short=4-HB polyprenyltransferase {ECO:0000255|HAMAP-Rule:MF_03189};
DE            EC=2.5.1.39 {ECO:0000255|HAMAP-Rule:MF_03189, ECO:0000269|PubMed:15153069, ECO:0000269|PubMed:16400613, ECO:0000269|PubMed:17374725};
DE   AltName: Full=4-hydroxybenzoate decaprenyltransferase {ECO:0000255|HAMAP-Rule:MF_03189};
DE   AltName: Full=COQ2 homolog;
DE            Short=hCOQ2;
DE   AltName: Full=Para-hydroxybenzoate--polyprenyltransferase {ECO:0000255|HAMAP-Rule:MF_03189};
DE            Short=PHB:PPT {ECO:0000255|HAMAP-Rule:MF_03189};
DE            Short=PHB:polyprenyltransferase {ECO:0000255|HAMAP-Rule:MF_03189};
DE   Flags: Precursor;
GN   Name=COQ2 {ECO:0000255|HAMAP-Rule:MF_03189}; Synonyms=CL640;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Liver, and Muscle;
RX   PubMed=15153069; DOI=10.1042/BJ20040261;
RA   Forsgren M., Attersand A., Lake S., Gruenler J., Swiezewska E.,
RA   Dallner G., Climent I.;
RT   "Isolation and functional expression of human COQ2, a gene encoding a
RT   polyprenyl transferase involved in the synthesis of CoQ2.";
RL   Biochem. J. 382:519-526(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, Melanoma, and Pancreatic carcinoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 104-334 (ISOFORM 3).
RA   Barrow I.K.-P., Boguski M.S., Touchman J.W., Spencer F.;
RT   "Full-insert sequence of mapped XREF EST.";
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 198-371 (ISOFORM 3).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   CHARACTERIZATION OF VARIANTS COQ10D1 CYS-247, FUNCTION, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=17374725; DOI=10.1093/hmg/ddm058;
RA   Lopez-Martin J.M., Salviati L., Trevisson E., Montini G., DiMauro S.,
RA   Quinzii C., Hirano M., Rodriguez-Hernandez A., Cordero M.D.,
RA   Sanchez-Alcazar J.A., Santos-Ocana C., Navas P.;
RT   "Missense mutation of the COQ2 gene causes defects of bioenergetics
RT   and de novo pyrimidine synthesis.";
RL   Hum. Mol. Genet. 16:1091-1097(2007).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY, AND CHARACTERIZATION OF
RP   VARIANTS COQ10D1 VAL-78; ASN-96; ARG-132; HIS-147; SER-178; CYS-247
RP   AND VAL-252.
RX   PubMed=27493029; DOI=10.1093/hmg/ddw257;
RA   Desbats M.A., Morbidoni V., Silic-Benussi M., Doimo M., Ciminale V.,
RA   Cassina M., Sacconi S., Hirano M., Basso G., Pierrel F., Navas P.,
RA   Salviati L., Trevisson E.;
RT   "The COQ2 genotype predicts the severity of coenzyme Q10 deficiency.";
RL   Hum. Mol. Genet. 25:4256-4265(2016).
RN   [8]
RP   VARIANT COQ10D1 CYS-247, CHARACTERIZATION OF VARIANT COQ10D1 CYS-247,
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=16400613; DOI=10.1086/500092;
RA   Quinzii C., Naini A., Salviati L., Trevisson E., Navas P., Dimauro S.,
RA   Hirano M.;
RT   "A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2)
RT   causes primary coenzyme Q10 deficiency.";
RL   Am. J. Hum. Genet. 78:345-349(2006).
RN   [9]
RP   VARIANTS COQ10D1 ASN-96; HIS-147; SER-178 AND CYS-247.
RX   PubMed=17855635; DOI=10.1681/ASN.2006080833;
RA   Diomedi-Camassei F., Di Giandomenico S., Santorelli F.M., Caridi G.,
RA   Piemonte F., Montini G., Ghiggeri G.M., Murer L., Barisoni L.,
RA   Pastore A., Muda A.O., Valente M.L., Bertini E., Emma F.;
RT   "COQ2 nephropathy: a newly described inherited mitochondriopathy with
RT   primary renal involvement.";
RL   J. Am. Soc. Nephrol. 18:2773-2780(2007).
RN   [10]
RP   VARIANT COQ10D1 VAL-252.
RX   PubMed=23343605; DOI=10.1016/j.jns.2013.01.004;
RA   Jakobs B.S., van den Heuvel L.P., Smeets R.J., de Vries M.C., Hien S.,
RA   Schaible T., Smeitink J.A., Wevers R.A., Wortmann S.B.,
RA   Rodenburg R.J.;
RT   "A novel mutation in COQ2 leading to fatal infantile multisystem
RT   disease.";
RL   J. Neurol. Sci. 326:24-28(2013).
RN   [11]
RP   VARIANTS MSA1 LEU-29; HIS-49; THR-57; VAL-78; THR-97; SER-107;
RP   PHE-113; ALA-267; CYS-297; GLN-337 AND ALA-343, AND VARIANTS VAL-16;
RP   LEU-22; HIS-69 AND HIS-336.
RX   PubMed=23758206; DOI=10.1056/NEJMoa1212115;
RG   Multiple-System Atrophy Research Collaboration;
RT   "Mutations in COQ2 in familial and sporadic multiple-system atrophy.";
RL   N. Engl. J. Med. 369:233-244(2013).
RN   [12]
RP   VARIANT COQ10D1 ARG-132.
RX   PubMed=25564041; DOI=10.1038/ejhg.2014.277;
RA   Desbats M.A., Vetro A., Limongelli I., Lunardi G., Casarin A.,
RA   Doimo M., Spinazzi M., Angelini C., Cenacchi G., Burlina A.,
RA   Rodriguez Hernandez M.A., Chiandetti L., Clementi M., Trevisson E.,
RA   Navas P., Zuffardi O., Salviati L.;
RT   "Primary coenzyme Q10 deficiency presenting as fatal neonatal
RT   multiorgan failure.";
RL   Eur. J. Hum. Genet. 23:1254-1258(2015).
RN   [13]
RP   VARIANT COQ10D1 ALA-340.
RX   PubMed=28044327; DOI=10.1111/cge.12960;
RA   Gigante M., Diella S., Santangelo L., Trevisson E., Acosta M.J.,
RA   Amatruda M., Finzi G., Caridi G., Murer L., Accetturo M., Ranieri E.,
RA   Ghiggeri G.M., Giordano M., Grandaliano G., Salviati L., Gesualdo L.;
RT   "Further phenotypic heterogeneity of CoQ10 deficiency associated with
RT   steroid resistant nephrotic syndrome and novel COQ2 and COQ6
RT   variants.";
RL   Clin. Genet. 0:0-0(2017).
CC   -!- FUNCTION: Catalyzes the prenylation of para-hydroxybenzoate (PHB)
CC       with an all-trans polyprenyl group. Mediates the second step in
CC       the final reaction sequence of coenzyme Q (CoQ) biosynthesis,
CC       which is the condensation of the polyisoprenoid side chain with
CC       PHB, generating the first membrane-bound Q intermediate.
CC       {ECO:0000255|HAMAP-Rule:MF_03189, ECO:0000269|PubMed:15153069,
CC       ECO:0000269|PubMed:16400613, ECO:0000269|PubMed:17374725,
CC       ECO:0000269|PubMed:27493029}.
CC   -!- CATALYTIC ACTIVITY: A polyprenyl diphosphate + 4-hydroxybenzoate =
CC       diphosphate + a 4-hydroxy-3-polyprenylbenzoate.
CC       {ECO:0000255|HAMAP-Rule:MF_03189, ECO:0000269|PubMed:15153069,
CC       ECO:0000269|PubMed:16400613, ECO:0000269|PubMed:17374725}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_03189};
CC   -!- PATHWAY: Cofactor biosynthesis; ubiquinone biosynthesis.
CC       {ECO:0000255|HAMAP-Rule:MF_03189}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane
CC       {ECO:0000255|HAMAP-Rule:MF_03189, ECO:0000269|PubMed:27493029};
CC       Multi-pass membrane protein {ECO:0000255|HAMAP-Rule:MF_03189};
CC       Matrix side {ECO:0000255|HAMAP-Rule:MF_03189}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96H96-1; Sequence=Displayed;
CC       Name=3;
CC         IsoId=Q96H96-3; Sequence=VSP_017677, VSP_017678;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Present in all of the
CC       tissues tested. Expressed at higher level in skeletal muscle,
CC       adrenal glands and the heart. {ECO:0000269|PubMed:15153069}.
CC   -!- DISEASE: Coenzyme Q10 deficiency, primary, 1 (COQ10D1)
CC       [MIM:607426]: An autosomal recessive disorder with variable
CC       manifestations consistent with 5 major phenotypes. The phenotypes
CC       include an encephalomyopathic form with seizures and ataxia; a
CC       multisystem infantile form with encephalopathy, cardiomyopathy and
CC       renal failure; a predominantly cerebellar form with ataxia and
CC       cerebellar atrophy; Leigh syndrome with growth retardation; and an
CC       isolated myopathic form. {ECO:0000269|PubMed:16400613,
CC       ECO:0000269|PubMed:17374725, ECO:0000269|PubMed:17855635,
CC       ECO:0000269|PubMed:23343605, ECO:0000269|PubMed:25564041,
CC       ECO:0000269|PubMed:27493029, ECO:0000269|PubMed:28044327}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Multiple system atrophy 1 (MSA1) [MIM:146500]: A
CC       progressive neurodegenerative disorder clinically characterized by
CC       parkinsonism, cerebellar ataxia, and autonomic, urogenital, and
CC       pyramidal dysfunction in various combinations. Pathologically, it
CC       is characterized by degeneration of striatonigral and
CC       olivopontocerebellar structures, and glial cytoplasmic inclusions
CC       that consist of abnormally phosphorylated alpha-synuclein or tau.
CC       {ECO:0000269|PubMed:23758206}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the UbiA prenyltransferase family.
CC       {ECO:0000255|HAMAP-Rule:MF_03189}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC72955.1; Type=Frameshift; Positions=172; Evidence={ECO:0000305};
CC       Sequence=AAH20728.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAF18241.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ621061; CAF18241.1; ALT_INIT; mRNA.
DR   EMBL; AC114781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC008804; AAH08804.1; -; mRNA.
DR   EMBL; BC020728; AAH20728.2; ALT_INIT; mRNA.
DR   EMBL; BC116454; AAI16455.1; -; mRNA.
DR   EMBL; AF091086; AAC72955.1; ALT_FRAME; mRNA.
DR   EMBL; CR456860; CAG33141.1; -; mRNA.
DR   RefSeq; NP_056512.5; NM_015697.7.
DR   UniGene; Hs.144304; -.
DR   UniGene; Hs.729069; -.
DR   ProteinModelPortal; Q96H96; -.
DR   BioGrid; 118083; 16.
DR   STRING; 9606.ENSP00000310873; -.
DR   iPTMnet; Q96H96; -.
DR   PhosphoSitePlus; Q96H96; -.
DR   DMDM; 74731901; -.
DR   MaxQB; Q96H96; -.
DR   PaxDb; Q96H96; -.
DR   PeptideAtlas; Q96H96; -.
DR   PRIDE; Q96H96; -.
DR   DNASU; 27235; -.
DR   Ensembl; ENST00000311469; ENSP00000310873; ENSG00000173085.
DR   Ensembl; ENST00000439031; ENSP00000409275; ENSG00000173085.
DR   GeneID; 27235; -.
DR   KEGG; hsa:27235; -.
DR   UCSC; uc003hog.3; human. [Q96H96-1]
DR   CTD; 27235; -.
DR   DisGeNET; 27235; -.
DR   GeneCards; COQ2; -.
DR   H-InvDB; HIX0004341; -.
DR   HGNC; HGNC:25223; COQ2.
DR   HPA; HPA056599; -.
DR   HPA; HPA068727; -.
DR   MalaCards; COQ2; -.
DR   MIM; 146500; phenotype.
DR   MIM; 607426; phenotype.
DR   MIM; 609825; gene.
DR   neXtProt; NX_Q96H96; -.
DR   Orphanet; 255249; Leigh syndrome with nephrotic syndrome.
DR   Orphanet; 227510; Multiple system atrophy, cerebellar type.
DR   Orphanet; 98933; Multiple system atrophy, parkinsonian type.
DR   PharmGKB; PA142672084; -.
DR   eggNOG; KOG1381; Eukaryota.
DR   eggNOG; COG0382; LUCA.
DR   HOGENOM; HOG000003697; -.
DR   HOVERGEN; HBG081302; -.
DR   InParanoid; Q96H96; -.
DR   KO; K06125; -.
DR   OrthoDB; EOG091G0K82; -.
DR   PhylomeDB; Q96H96; -.
DR   TreeFam; TF105873; -.
DR   BioCyc; MetaCyc:ENSG00000173085-MONOMER; -.
DR   BRENDA; 2.5.1.39; 2681.
DR   Reactome; R-HSA-1268020; Mitochondrial protein import.
DR   Reactome; R-HSA-2142789; Ubiquinol biosynthesis.
DR   UniPathway; UPA00232; -.
DR   GeneWiki; COQ2; -.
DR   GenomeRNAi; 27235; -.
DR   PRO; PR:Q96H96; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000173085; -.
DR   CleanEx; HS_COQ2; -.
DR   ExpressionAtlas; Q96H96; baseline and differential.
DR   Genevisible; Q96H96; HS.
DR   GO; GO:0031305; C:integral component of mitochondrial inner membrane; IDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; TAS:Reactome.
DR   GO; GO:0002083; F:4-hydroxybenzoate decaprenyltransferase activity; IMP:UniProtKB.
DR   GO; GO:0047293; F:4-hydroxybenzoate nonaprenyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0006071; P:glycerol metabolic process; IGI:UniProtKB.
DR   GO; GO:0008299; P:isoprenoid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0006744; P:ubiquinone biosynthetic process; IDA:UniProtKB.
DR   HAMAP; MF_01635; UbiA; 1.
DR   InterPro; IPR031103; HB_octoprenylTrfase.
DR   InterPro; IPR006370; HB_polyprenyltransferase.
DR   InterPro; IPR000537; UbiA_prenyltransferase.
DR   InterPro; IPR030470; UbiA_prenylTrfase_CS.
DR   Pfam; PF01040; UbiA; 1.
DR   TIGRFAMs; TIGR01474; ubiA_proteo; 1.
DR   PROSITE; PS00943; UBIA; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disease mutation;
KW   Isoprene biosynthesis; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Neurodegeneration; Parkinsonism;
KW   Polymorphism; Reference proteome; Transferase; Transit peptide;
KW   Transmembrane; Transmembrane helix; Ubiquinone biosynthesis.
FT   TRANSIT       1     34       Mitochondrion. {ECO:0000255|HAMAP-
FT                                Rule:MF_03189}.
FT   CHAIN        35    371       4-hydroxybenzoate polyprenyltransferase,
FT                                mitochondrial. {ECO:0000255|HAMAP-
FT                                Rule:MF_03189}.
FT                                /FTId=PRO_0000228623.
FT   TOPO_DOM     35     83       Mitochondrial matrix.
FT                                {ECO:0000305|PubMed:27493029}.
FT   TRANSMEM     84    104       Helical. {ECO:0000255|HAMAP-
FT                                Rule:MF_03189}.
FT   TOPO_DOM    105    108       Mitochondrial intermembrane.
FT                                {ECO:0000305|PubMed:27493029}.
FT   TRANSMEM    109    129       Helical. {ECO:0000255|HAMAP-
FT                                Rule:MF_03189}.
FT   TOPO_DOM    130    148       Mitochondrial matrix.
FT                                {ECO:0000305|PubMed:27493029}.
FT   TRANSMEM    149    169       Helical. {ECO:0000255|HAMAP-
FT                                Rule:MF_03189}.
FT   TOPO_DOM    170    172       Mitochondrial intermembrane.
FT                                {ECO:0000305|PubMed:27493029}.
FT   TRANSMEM    173    193       Helical. {ECO:0000255|HAMAP-
FT                                Rule:MF_03189}.
FT   TOPO_DOM    194    203       Mitochondrial matrix.
FT                                {ECO:0000305|PubMed:27493029}.
FT   TRANSMEM    204    224       Helical. {ECO:0000255|HAMAP-
FT                                Rule:MF_03189}.
FT   TOPO_DOM    225    231       Mitochondrial intermembrane.
FT                                {ECO:0000305|PubMed:27493029}.
FT   TRANSMEM    232    252       Helical. {ECO:0000255|HAMAP-
FT                                Rule:MF_03189}.
FT   TOPO_DOM    253    277       Mitochondrial matrix.
FT                                {ECO:0000305|PubMed:27493029}.
FT   TRANSMEM    278    298       Helical. {ECO:0000255|HAMAP-
FT                                Rule:MF_03189}.
FT   TOPO_DOM    299    300       Mitochondrial intermembrane.
FT                                {ECO:0000305|PubMed:27493029}.
FT   TRANSMEM    301    321       Helical. {ECO:0000255|HAMAP-
FT                                Rule:MF_03189}.
FT   TOPO_DOM    322    332       Mitochondrial matrix.
FT                                {ECO:0000305|PubMed:27493029}.
FT   TRANSMEM    333    353       Helical. {ECO:0000255|HAMAP-
FT                                Rule:MF_03189}.
FT   TOPO_DOM    354    371       Mitochondrial intermembrane.
FT                                {ECO:0000269|PubMed:27493029}.
FT   REGION      122    144       Allylic polyprenyl diphosphate-binding
FT                                site. {ECO:0000255|HAMAP-Rule:MF_03189}.
FT   VAR_SEQ     318    334       IYTLDIHRPEDCWNKFI -> KWGLEILPRLV (in
FT                                isoform 3). {ECO:0000303|Ref.4,
FT                                ECO:0000303|Ref.5}.
FT                                /FTId=VSP_017677.
FT   VAR_SEQ     335    371       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.4, ECO:0000303|Ref.5}.
FT                                /FTId=VSP_017678.
FT   VARIANT      16     16       L -> V (in dbSNP:rs6818847).
FT                                {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070237.
FT   VARIANT      22     22       P -> L. {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070238.
FT   VARIANT      29     29       F -> L (in MSA1; associated with disease
FT                                susceptibility).
FT                                {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070239.
FT   VARIANT      49     49       P -> H (in MSA1; associated with disease
FT                                susceptibility).
FT                                {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070240.
FT   VARIANT      57     57       S -> T (in MSA1; associated with disease
FT                                susceptibility).
FT                                {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070241.
FT   VARIANT      69     69       R -> H. {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070242.
FT   VARIANT      78     78       M -> V (in MSA1; associated with disease
FT                                susceptibility; decreased ubiquinone
FT                                biosynthesis).
FT                                {ECO:0000269|PubMed:23758206,
FT                                ECO:0000269|PubMed:27493029}.
FT                                /FTId=VAR_070243.
FT   VARIANT      96     96       S -> N (in COQ10D1; decreased ubiquinone
FT                                biosynthesis).
FT                                {ECO:0000269|PubMed:17855635,
FT                                ECO:0000269|PubMed:27493029}.
FT                                /FTId=VAR_068161.
FT   VARIANT      97     97       I -> T (in MSA1; associated with disease
FT                                susceptibility).
FT                                {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070244.
FT   VARIANT     107    107       P -> S (in MSA1; associated with disease
FT                                susceptibility).
FT                                {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070245.
FT   VARIANT     113    113       S -> F (in MSA1; associated with disease
FT                                susceptibility).
FT                                {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070246.
FT   VARIANT     132    132       M -> R (in COQ10D1; decreased ubiquinone
FT                                biosynthesis).
FT                                {ECO:0000269|PubMed:25564041,
FT                                ECO:0000269|PubMed:27493029}.
FT                                /FTId=VAR_076913.
FT   VARIANT     147    147       R -> H (in COQ10D1; loss of ubiquinone
FT                                biosynthesis).
FT                                {ECO:0000269|PubMed:17855635,
FT                                ECO:0000269|PubMed:27493029}.
FT                                /FTId=VAR_068162.
FT   VARIANT     178    178       N -> S (in COQ10D1; decreased ubiquinone
FT                                biosynthesis).
FT                                {ECO:0000269|PubMed:17855635,
FT                                ECO:0000269|PubMed:27493029}.
FT                                /FTId=VAR_068163.
FT   VARIANT     247    247       Y -> C (in COQ10D1; decreased 4-
FT                                hydroxybenzoate decaprenyltransferase
FT                                activity). {ECO:0000269|PubMed:16400613,
FT                                ECO:0000269|PubMed:17374725,
FT                                ECO:0000269|PubMed:17855635,
FT                                ECO:0000269|PubMed:27493029}.
FT                                /FTId=VAR_025701.
FT   VARIANT     252    252       A -> V (in COQ10D1; loss of ubiquinone
FT                                biosynthesis).
FT                                {ECO:0000269|PubMed:23343605,
FT                                ECO:0000269|PubMed:27493029}.
FT                                /FTId=VAR_076914.
FT   VARIANT     267    267       T -> A (in MSA1; associated with disease
FT                                susceptibility).
FT                                {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070247.
FT   VARIANT     297    297       S -> C (in MSA1; associated with disease
FT                                susceptibility).
FT                                {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070248.
FT   VARIANT     336    336       N -> H. {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070249.
FT   VARIANT     337    337       R -> Q (in MSA1; associated with disease
FT                                susceptibility).
FT                                {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070250.
FT   VARIANT     340    340       G -> A (in COQ10D1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:28044327}.
FT                                /FTId=VAR_078121.
FT   VARIANT     343    343       V -> A (in MSA1; associated with disease
FT                                susceptibility).
FT                                {ECO:0000269|PubMed:23758206}.
FT                                /FTId=VAR_070251.
SQ   SEQUENCE   371 AA;  40489 MW;  92371F0DD373A732 CRC64;
     MLGSRAAGFA RGLRALALAW LPGWRGRSFA LARAAGAPHG GDLQPPACPE PRGRQLSLSA
     AAVVDSAPRP LQPYLRLMRL DKPIGTWLLY LPCTWSIGLA AEPGCFPDWY MLSLFGTGAI
     LMRGAGCTIN DMWDQDYDKK VTRTANRPIA AGDISTFQSF VFLGGQLTLA LGVLLCLNYY
     SIALGAGSLL LVITYPLMKR ISYWPQLALG LTFNWGALLG WSAIKGSCDP SVCLPLYFSG
     VMWTLIYDTI YAHQDKRDDV LIGLKSTALR FGENTKPWLS GFSVAMLGAL SLVGVNSGQT
     APYYAALGAV GAHLTHQIYT LDIHRPEDCW NKFISNRTLG LIVFLGIVLG NLWKEKKTDK
     TKKGIENKIE N
//
